A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Tumor response to DaRT
研究概览
简要总结
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
详细描述
This will be a prospective, open label, single arm, controlled study, assessing the safety and efficacy of diffusing alpha emitters radiation therapy (DaRT) delivered through radioactive seeds inserted into the tumor.
This approach combines the advantages of local intratumoral irradiation of the tumor, as used in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that will be introduced in quantities considerably lower than radiation therapy already used in patients.
Superficial lesions with histopathological confirmation of malignancy will be treated using DaRT seeds.
Reduction in tumor size 70 days after DaRT insertion will be assessed. Safety will be assessed by the incidence, severity and frequency of all Adverse Events (AE).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with histopathological confirmation of primary or secondary malignant cutaneous neoplastic lesions, or oral cavity mucosal tumors, or superficial soft tissue sarcoma.
- •Subjects with a tumor size ≤ 7 centimeters in the longest diameter.
- •Measurable disease according to RECIST v1.
- •Subjects over 18 years old.
- •Subjects' ECOG Performance Status Scale is <
- •Subjects' life expectancy is more than 6 months.
- •Platelet count ≥100,000/mm
- •International normalized ratio of prothrombin time ≤1.
- •Creatinine ≤1.9 mg/dL.
- •Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.
- •Subjects are willing to sign an informed consent form.
排除标准
- •Subject has a tumor of Keratoacanthoma histology.
- •Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)
- •Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids
- •Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
- •High probability of protocol non-compliance (in opinion of investigator).
- •Subjects not willing to sign an informed consent.
- •Women who are pregnant or breastfeeding.
结局指标
主要结局
Tumor response to DaRT
时间窗: 9-11 weeks after DaRT seed insertion.
Assessment of the rate of malignant cutaneous, mucosal or superficial soft tissue tumors response using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)
Adverse Events
时间窗: Time Frame: 9-11 weeks post DaRT insertion.
The incidence, frequency, severity and causality of acute adverse events related to the DaRT treatment
次要结局
- Assessment of the reduction in tumor volume(9-11 weeks follow-up visit.)
- DaRT seeds placement.(Day of insertion procedure.)
- Change in quality of life(Screening, DaRT removal and day 70 visits.)